A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital.

Authors: López-Medrano F,San Juan R,Lizasoain M,Catalán M,Ferrari JM,Chaves F,Lumbreras C,Montejo JC,Herreros de Tejada A,Aguado JM,
Address: Infectious Diseases Unit Intensive Care Unit Department of Pharmacy Department of Microbiology, University Hospital 12 de Octubre, Madrid, Spain.
Journal: Clin Microbiol Infect.

Publication: 2013 Jan;19(1):56-61. doi: 10.1111/j.1469-0691.2012.03891.x. Epub 2012 May 2.

abstract

Antimicrobial stewardship programmes promote excellence in the use of antimicrobials by selecting the appropriate antimicrobial agent and the correct dose, route of administration and duration of treatment. However, there is limited experience with such programmes targeting antifungal treatments. We present the results of a non-compulsory programme for the control of antifungals. For 12 months, prescriptions of oral voriconazole or intravenous voriconazole, caspofungin and liposomal amphotericin B were reviewed, and non-compulsory recommendations were made. The incidence and outcome of fungal infections were examined. The results for the dispensed defined daily doses (DDDs) and expenditure on antifungals were compared with those for the previous 12 months. The number of antifungal treatments reviewed was 662. A recommendation to change treatment was made in 29% of the cases, including a change from intravenous to oral treatment (15%), cessation of antifungal treatment (8%), and a change to fluconazole (6%). The DDDs of intravenous voriconazole and caspofungin were reduced by 31.4% and 20.2%, respectively. The DDDs of oral voriconazole and dispensed vials of liposomal amphotericin B were increased by 8.2% and 13.9%, respectively. Expenditure on antifungals was reduced by US$370681.78 (11.8% reduction). The programme was not related to significant increases in the incidence of candidaemia, percentage of persistent/relapsing candidaemia cases, percentage of fluconazole-resistant Candida species, incidence of infections by filamentous fungi, or 12-month mortality in patients with filamentous fungal infections. In conclusion, a stewardship programme targeting antifungals achieved a reduction in antifungal expenditure without reducing the quality of care provided.

Related Articles
Review Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Drugs. 2009
Review Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD, Lyseng-Williamson KA, Scott LJ. Drugs. 2009; 69(3):361-92.
Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Am J Ophthalmol. 2005
Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Am J Ophthalmol. 2005 Jan; 139(1):135-40.
Review Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
Cochrane Database Syst Rev. 2010
Review Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH. Cochrane Database Syst Rev. 2010 Feb 17; (2):CD006343. Epub 2010 Feb 17.
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Lancet. 2005
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, et al. Lancet. 2005 Oct 22-28; 366(9495):1435-42.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
N Engl J Med. 2002
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, et al. N Engl J Med. 2002 Jan 24; 346(4):225-34.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.